Bruno Costa Gabriel, managing director of Janssen Brazil, provides insights into the transformative market approach successfully implemented by this leading company in Brazil and his main priorities to further leverage the great potential of Janssen’s innovation and impact an ever-increasing number of Brazilian patients.
You display a truly international market perspective after having held senior positions at Janssen in various markets, including France, Portugal, Italy, Spain, and Puerto Rico – among others. What key specificities of the Brazilian market would you highlight to our international readers?
"As one of the world’s leading innovative companies, we have also broadened our R&D approach to Brazil by trying to more directly support local innovative projects, which we help scale up."
